Nuwellis says study backs epoprostenol as alternative anticoagulant for pediatric Aquadex ultrafiltration therapy
NUWE•Publication costs funded by Nuwellis
Nuwellis funded open-access publication costs, not the conduct of the research.
Study accepted by Frontiers in Pediatrics
Nuwellis disclosed acceptance by Frontiers in Pediatrics of a retrospective study on anticoagulation during Aquadex ultrafiltration in critically ill children.
Results were already generated in routine care, not a prospective trial; publication is pending following journal acceptance.
Epoprostenol kept circuits functioning without added bleeding risk
The study found epoprostenol kept Aquadex circuits functioning without added bleeding risk or greater need for blood-pressure support.
Findings support an alternative anticoagulation option for pediatric patients who may not be suitable for conventional approaches, potentially widening Aquadex use.
